In this article, we will be looking at the 10 Best Medical Stocks to Buy Under $30.
On April 28, Reuters reported that the US Food and Drug Administration has introduced a new pilot program that would allow the agency to monitor clinical trial data in real time. The agency believes this step could reduce the time it takes to approve new drugs by years and help the US stay competitive with China.
In a call with reporters, FDA Commissioner Marty Makary said the aim of this initiative is to remove “dead time” in the drug development process. He explained that administrative tasks and paperwork make up about 45% of the time needed to move a drug from early testing to submission for an approval decision.
The FDA has published a request for information for input from the public and industry for expanding the pilot program. The agency said that it will accept comments until May 29. It plans to finalize its selection criteria in July and complete pilot selections in August.
Makary also pointed to rising international competition and noted that China overtook the US in the number of Phase 1 clinical trials being conducted around 2021. He added that China’s growth has since been exponential.
With this background in mind, let’s take a look at the 10 best medical stocks to buy under $30.
Our Methodology
To compile our list of the 10 best medical stocks to buy under $30, we used the Finviz stock screener to look for medical stocks with a share price of under $30 as of April 27, 2026. We sorted our results based on market capitalization and picked the top medical stocks. Next, we focused on the top 10 stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q4 2025 database of 1041 elite hedge funds. Finally, the 10 best medical stocks to buy under $30 were ranked in ascending order based on the number of hedge funds holding stakes in them as of Q4 2025.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Medical Stocks to Buy Under $30
10. Enovis Corporation (NYSE:ENOV)
Enovis Corporation (NYSE:ENOV) is one of the best medical stocks to buy under $30. On April 17, William Blair initiated coverage on Enovis Corporation (NYSE:ENOV), giving the stock an Outperform rating. The research firm pointed to valuation opportunities after the stock has dropped over the past two years.
William Blair said that Enovis Corporation (NYSE:ENOV) is trading at a price-to-earnings ratio of 9 times trailing earnings per share, including stock-based compensation. This is lower than the average of around 15.5 times for peers.
The research firm said that improving free cash flow will be the most important variable for Enovis Corporation’s (NYSE:ENOV) valuation to rise. Management guided free cash flow conversion to reach about 25% in 2026, compared to 10% in 2025. William Blair believes this target is achievable because of reduced cash charges from last year.
Additionally, William Blair supported management’s more conservative growth outlook for 2026, which is projected at 4% to 6%. This is lower than the guidance of more than 6% that the company gave heading into 2024 and 2025. The research firm believes that Enovis Corporation’s (NYSE:ENOV) valuation shows that investors are still skeptical about the company’s performance.
Enovis Corporation (NYSE:ENOV) is a medical technology company focused on developing clinically differentiated solutions in orthopedics and beyond.
9. Azenta, Inc. (NASDAQ:AZTA)
Azenta, Inc. (NASDAQ:AZTA) is one of the best medical stocks to buy under $30. On April 6, Evercore ISI reduced its price target on Azenta, Inc. (NASDAQ:AZTA) from $45 to $35 while maintaining its Outperform rating on the stock. This update came as part of the firm’s first-quarter preview for the medical technology and life science tools sector.
In other news, Azenta, Inc. (NASDAQ:AZTA) announced that Trey Martin has been appointed President of its Multiomics business, effective April 6, 2026. In this new role, Martin will lead the Multiomics division and report directly to the company’s President and Chief Executive Officer, John Marotta.
According to the report by Azenta, Inc. (NASDAQ:AZTA), this appointment is aimed at speeding up progress on its long-range Multiomics plan, which was outlined at the company’s Investor Day in December 2025. The plan focuses on expanding global synthesis capabilities, improving operations, strengthening commercial execution, and driving profitable growth across its integrated Multiomics platform to support performance and wider market adoption.
Meanwhile, Ginger Zhou will step down as President of the Multiomics business but will stay with the company in an advisory capacity through November 2026 to help ensure a smooth transition as the business moves into its next phase of execution.
Azenta, Inc. (NASDAQ:AZTA) is a life sciences company that offers a wide range of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic and healthcare institutions around the world.
